Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1208-1209

  Lê, Minh P ^a   Gervais, Anne ^a   Le beller, Christine ^b   Long, Kivan ^a   Larrouy, Lucile ^a   Papy, Emmanuelle ^a   Mal, Hervé ^a   Descamps, Diane ^a   Peytavin, Gilles ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antiviral therapy; Drug interactions; HBV; HCV

Indexed keywords

BOSENTAN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; PEGINTERFERON ALPHA2A; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; TELAPREVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BALANCE DISORDER; BLURRED VISION; CASE REPORT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; CONFUSION; DIZZINESS; ESOPHAGUS VARICES; FRANCE; GAIT DISORDER; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOTENSION; LETTER; MALE; MIXED INFECTION; PREVALENCE; PULMONARY HYPERTENSION; SIDE EFFECT; SURVIVAL RATE;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OLIGOPEPTIDES; SULFONAMIDES;

EID: 84877155913     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks518     Document Type: Letter

References (10)

1. Savale L, Lador F, Jais X et al. HIV-related pulmonary arterial hypertension. Rev Mal Respir 2012; 4: 491-500.
2. Lausecker B, Hess B, Fischer G et al. Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 2000; 749: 67-83.
3. Farnik H, El-Duweik J, Welsch C et al. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 4001-6.
4. Jung BH, Rezk NL, Bridges AS et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21: 1095-104.
5. Incivek (Telaprevir). Food and Drug Administration, Label Information 2011. Janssen-Cilag International NV, Beerse, Belgium.
6. Burgess G, Hoogkamer H, Collings L et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64: 43-50.
7. de Kanter CT, Blonk MI, Colbers AP et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 2013; 56: 300-6.
8. van Heeswijk R, Garg V, Boogaerts G et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011. Abstract 1738a. American Society for Microbiology, Washington, DC, USA.
9. Buckley MS, Wicks LM, Staib RL et al. Pharmacokinetic evaluation of ambrisentan. Expert Opin Drug Metab Toxicol 2011; 7: 371-80.
10. Dingemanse J, van Giersbergen PL, Patat A et al. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther 2010; 15: 157-63.